Rivfloza

blood disorders genetic disorders rare disease

Pharma

Amid ongoing launches, Novo eyes rare disease leadership

As Novo advances its rare disease ambitions, the success of a hemophilia launch and late-stage sickle cell disease trial will be key.

Fraiser Kansteiner Mar 7, 2025 9:20am

Novo Nordisk

Novo Nordisk eyes showdown with Alnylam with new FDA nod

Oct 2, 2023 1:36pm